🚀 VC round data is live in beta, check it out!
Prescient Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prescient Therapeutics and similar public comparables like INmune Bio, Imugene, Mabion, Sprint Bioscience and more.
Prescient Therapeutics Overview
About Prescient Therapeutics
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Founded
1986
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$32M
Prescient Therapeutics Stock Performance
Prescient Therapeutics has current market cap of $38M, and enterprise value of $32M.
Market Cap Evolution
Prescient Therapeutics' stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $38M | -2.2% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrescient Therapeutics Valuation Multiples
Prescient Therapeutics Financial Valuation Multiples
As of April 18, 2026, Prescient Therapeutics has market cap of $38M and EV of $32M.
Equity research analysts estimate Prescient Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prescient Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prescient Therapeutics Margins & Growth Rates
Prescient Therapeutics' revenue in the last fiscal year grew by —.
Prescient Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 4% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prescient Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| Sprint Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Veru | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prescient Therapeutics M&A Activity
Prescient Therapeutics acquired XXX companies to date.
Last acquisition by Prescient Therapeutics was on XXXXXXXX, XXXXX. Prescient Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prescient Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrescient Therapeutics Investment Activity
Prescient Therapeutics invested in XXX companies to date.
Prescient Therapeutics made its latest investment on XXXXXXXX, XXXXX. Prescient Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prescient Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prescient Therapeutics
| When was Prescient Therapeutics founded? | Prescient Therapeutics was founded in 1986. |
| Where is Prescient Therapeutics headquartered? | Prescient Therapeutics is headquartered in Australia. |
| How many employees does Prescient Therapeutics have? | As of today, Prescient Therapeutics has over 1 employees. |
| Is Prescient Therapeutics publicly listed? | Yes, Prescient Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Prescient Therapeutics? | Prescient Therapeutics trades under PTX ticker. |
| When did Prescient Therapeutics go public? | Prescient Therapeutics went public in 1986. |
| Who are competitors of Prescient Therapeutics? | Prescient Therapeutics main competitors are INmune Bio, Imugene, Mabion, Sprint Bioscience. |
| What is the current market cap of Prescient Therapeutics? | Prescient Therapeutics' current market cap is $38M. |
| Is Prescient Therapeutics profitable? | No, Prescient Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.